Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. [electronic resource]
- Neuroscience Oct 2011
- 399-410 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1873-7544
10.1016/j.neuroscience.2011.07.039 doi
Analysis of Variance Animals Animals, Newborn Brain-Derived Neurotrophic Factor--pharmacology Bromodeoxyuridine--metabolism Cells, Cultured Cyclic Nucleotide Phosphodiesterases, Type 5--metabolism Diabetes Complications--physiopathology Diabetic Neuropathies--drug therapy Disease Models, Animal Dose-Response Relationship, Drug Gene Expression Regulation--drug effects Hyperalgesia--drug therapy Male Mice Mice, Inbred C57BL Mice, Neurologic Mutants Nerve Tissue Proteins--metabolism Neural Conduction--drug effects Pain Measurement--methods Pain Threshold--drug effects Phosphodiesterase 5 Inhibitors--therapeutic use Piperazines--therapeutic use Purines--therapeutic use RNA, Small Interfering--genetics Receptors, Leptin--deficiency Schwann Cells--drug effects Sciatic Neuropathy--drug therapy Sildenafil Citrate Sulfones--therapeutic use Time Factors Transfection--methods